Candel is a late stage clinical biotechnology company developing oncolytic viral immunotherapies for the treatment of high unmet need cancers such as prostate and glioblastoma.
ChromaCode expands the number of samples a lab can process when using the same equipment and lab technicians, without sacrificing accuracy.
Current Health is an enterprise remote care management platform enabling early, preventive health care at home to improve health outcomes and reduce the cost of care.
Deep Lens enables care teams to find the best available clinical trials for a patient’s specific diagnosis – at the time of diagnosis.
Delfi Diagnostics detects cancer sooner, enabling the most informed treatment decision.
DICE enables the convenience of an oral medicine with the efficacy of existing biologics to create new medicines for patients suffering from debilitating autoimmune diseases.
Eleanor Health is the first evidence-based, whole-person care model for individuals and populations with substance use disorders and mental health needs.
Faro Health simplifies the design and authoring of complex clinical trials by harnessing the power of smart digital protocols.
Hawthorne Effect is making clinical trials accessible and convenient for everyone, everywhere.
Inflammatix develops rapid tests to read a patient’s immune system to better characterize diseases, such as sepsis and fever of unknown origin.
Kyverna is a clinical-stage cell therapy company advancing a new class of curative therapies for inflammatory and autoimmune diseases.
Octave is developing an integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases.
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics targeting multiple drivers of cancer.
Outcomes4Me developed an AI-powered platform to empower cancer patients to navigate their care and achieve better outcomes.
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analysis to help clinicians and researchers provide more informed treatment selection, sooner.
Saama is an AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.
Scipher has built a diagnostic platform that analyzes a patient’s individual molecular data to ensure optimal therapy is prescribed.
Selux is developing a rapid solution for antibiotic susceptibility testing, which affects millions of patients who suffer from infection when resistant to available antibiotics.
Sherlock is developing a molecular diagnostics platform that enables instrument-free, simple-to-operate tests that can be applied across multiple diseases and in both clinical and non-clinical settings.
SimBioSys enables cancerous tumors to be visualized, helping predict a patient’s unique response to treatment.
SpeeDx developed a diagnostics platform, principally for infectious diseases, that provides both identification and therapeutic guidance capabilities in the same simplified workflow.
Story Health brings the specialty clinic to the home, bridging the gap between patients and providers with connected devices, virtual patient engagement, and AI-powered clinical decision support.
Syapse works with health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients.
Teckro is modernizing and simplifying clinical research to help make clinical trials more simple, accessible, and transparent.
Torus Biosystems created a multiplex syndromic testing system, giving clinicians the necessary tools to rapidly diagnose infectious diseases at the point of care.
Totus scalably invents covalent medicines with the potential for superior safety and efficacy.
Triumvira is a clinical stage oncology cell therapy company developing a pipeline of novel autologous and allogeneic therapies with enhanced safety and efficacy over current approaches.
VieCure is an AI-powered platform that integrates data from oncology patients’ health records, including genomic sequencing, to generate real-time, patient-specific, actionable, and comprehensive treatment plans.
Vigil Neuroscience is the world’s first microglia-focused biotechnology company focused on treating rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system.
Vital Bio is reimagining the status quo of lab testing through an ecosystem of diagnostic tools that enable patients to get real-time care that is accessible and empowering.